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Effects of deferoxamine, feroxamine and iron on experimental mu-
cormycosis (zygomycosis). Mucormycosis was induced in healthy guinea
pigs by the i.v. injection of spores from Rhizopus microsporus var.
rhizopodformis or from Rhizopus oryzae, leading to a reproducible
mortality. Pretreatment with one dose of 50 mg of deferoxamine (DFO)
shortened animal survival from 4.2 0.4 to 3.3 0.5 days for Rh.
rhizopodformis and from 8.8 0.4 to 7.3 1.9 days for Rh. oryzae (P
<0.05). Survival was shortened even more after 4 doses of DFO (P =
0.0013 for Rh. rhizopodiformis and P = 0.002 for Rh. oryzae). After Rh.
oryzae infection, animal survival decreased similarly after DFO, ferox-
amine or DFO combined with Fe3 citrate (P <0.001). Fe3 citrate also
decreased survival (P = 0.0011), although significantly less than DFO
either alone or combined with Fe3. In vitro growth of both fungal
strains was enhanced by addition of either DFO or Fe3 at 0.001 to 1
mmol in the medium. DFO abolished the prolonged survival induced by
amphotericin B in vivo and in vitro. Indeed, four doses of DFO
abolished the improved survival due to amphotericin B (P = 0.0019 for
Rh. rhizopodiformis and P = 0.002 for Rh. orvzae); DFO combined with
Fe3 at 0. 1 mmol decreased the antifungal activity of amphotericin B
in vitro. These results point to a major role of DFO in the pathogenesis
of mucormycosis in dialysis patients and suggest that DFO behaves as
a siderophore for Rhizopus strains, stimulating their growth.
Recently, several reports worldwide have described mu-
cormycosis (zygomycosis) in non-diabetic patients on main-
tenance hemodialysis [reviewed in 1; 2—71. There is a striking
association between the occurrence of this severe infection in
dialysis patients and the use of deferoxamine (DFO) in the
treatment of aluminum overload, iron excess or both [1—7].
Indeed, 22 of 25 dialysis patients reported up to February 1989
to have this infection were receiving DFO. In all dialysis
patients with mucormycosis for whom culture results of the
phycomycete fungus were reported, the genus Rhizopus was
found, although several other genera or species are able to
cause human zygomycosis [81. The mechanism(s) by which
DFO could favor a Rhizopus infection in DFO-treated dialysis
patients is (are) unknown. Up to now, the effect of DFO on
experimental infections with Rhizopus has not been examined.
In the present study, a reproducible model of disseminated
mucormycosis, obtained by intravenous injection of Rhizopus
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spores in the guinea pig was used. In this non-uremic animal
model, DFO enhanced the infection, shortened survival of the
infected guinea pigs, and decreased the effectiveness of therapy
with amphotericin B.
Methods
Fun gal strains and inoculum
Two clinical isolates of the genus Rhizopus were used. The
first was Rhizopus microsporus, var. rhizopodiformis B 51321
(RV 62915), which was isolated from a dialysis patient reported
to have died from mucormycosis while being treated with DFO
[case no. 2 of ref. 1]. This strain will further be referred to as
Rh. rhizopodiformis. The second was Rhizopus oryzae B 51322
(RV 49151), which was isolated from a leukemic patient who
died from mucormycosis in the absence of DFO treatment.
Both isolates were provided by Prof. Ch. De Vroey, Laboratory
for Mycology, Institute for Tropical Medicine, Antwerp, Be!-
gium and were stored on Sabouraud agar medium.
In vitro experiments
All in vitro experiments for growth evaluation and for anti-
fungal activity were performed in Sabouraud broth (Difco 1%
neopeptone and 2% glucose) with a content of 0.41 to 0.45 ppm
of iron, as measured by atomic absorption spectrometry. The
medium was unbuffered at the start, and the pH of the inocu-
lated non-medicated medium was determined at regular inter-
vals (Metrohm 654). Amphotericin B (Fungizone® ad perfu-
sionem, Squibb, batch No. 88B29, expiration date 02/90) was
dissolved in sterile distilled water and serially diluted from 100
g. ml to 0.1 sg. m1' in Sabouraud broth medium.
Deferoxamine (Desferal®, Ciba-Geigy, batch 87101, expira-
tion date 09/91) and iron (III) citrate hydrate (Fe3)
(C6H3O7Fe.5/2H,O, Janssen Chimica Ref. No. 2118539, 18 to
20% Fe) were dissolved at 10 mmol in distilled water, sterilized
by Seitz filtration and distributed in the medium at final con-
centrations of 1, 0.1, 0.01, 0.001 and 0 mmol.
The tubes contained 4.5 ml of Sabouraud broth plus 0.5 ml of
dilutions of either amphotericin B, or DFO, or Fe3, or
amphotericin B + DFO + Fe3 at various concentrations.
Combining DFO and Fe3 citrate hydrate in stoichiometric
quantities generated feroxamine (FO).
Drug treated and untreated (control) tubes were inoculated
with a square block of 2 mm side, containing hyphae and spores
of Rh. rhizopodiformis or Rh. oryzae, and their content was
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Table 1. Systemic zygomycosis induced by Rhizopus microsporus var. rhizopodiformis in guinea pigs (groups of 6): Treatment with
deferoxamine and amphotericin B
Cultures
Group Infection
Treatment
DFO Therapy
Survivors
no.
.Mean survival
in days
day 28
•Statist bics: P
No. of pos. organs
.(7 per animal )
dead surviving
.Statistics:
vs. group 5vs. group 3 vs. group 5
1 0 0 0 6 28 — 0/42
(saline)
2 0 0 A'1 6 28 — 0/42
3 + 0 0 0 4.2 (0.41)e 40/42 —
4 + 0 saline 0 4.2 (1.17) 38/42 —
5 + 0 A 5 25.5 (6.2) 0.002 2/7 5/35
6 + 1 0 0 3.3 (0.52) 0.018 36/42 —
7 + 1 A 0 4.8 (2.14) 0.003 37/42 — <0.001
8 + 2 0 0 3.0(0) 0.0013 36/42 —
9 + 2 A 0 3.2 (0.17) 0.006 0.0019 40/42 — <0.001
10 + 4 0 0 3.0 (0) 0.0013 42/42 —
11 + 4 A 0 3.2 (0.17) 0.006 0.0019 37/42 — <0.001
12 0 1 0 6 28 — 0/42
13 0 4 0 6 28 — 0/42
a Deferoxamine, 50 mg i.m. per injectionb Mann-Whitney U test (two-tailed probability) for comparing survival; Chi-square test (two-tailed probability) for comparing culture results
7 organs: lungs, liver, spleen, left kidney, brain, skin and left eye (6 animals per group)d Amphotericin B, 2.5 mg g' i.p. during 14 days, starting on the day of infection
(0.41): standard deviation
homogenized by vortex. The tubes were incubated for two
weeks at 25°C and at 37°C. Fungal development was scored on
days 2, 3, 4, 5, 6, 7 and 14. The cultures were considered to
reach 100% growth when hyphal development in the broth was
intense and when the surface was completely covered with
aerial mycelium. When abundant sporulation occurred, a score
of 110% was given. All experiments were duplicated.
In vivo experiments
Animals. Normal male Albino guinea pigs (Pirbright strain) of
500 g 50 g were infected intravenously with 293 colony
forming units (CFU) of Rh. rhizopodfor,nis per g body weight
and with 3,550 CFU of Rh. oryzae per g body weight. The
inoculum was administered in saline (1 ml vol) in a lateral vein
of the penis. These inocula were obtained from fungal cultures
grown for seven days at 37°C in Roux bottles with Sabouraud
agar. Sporangiospores were harvested by shaking gently after
adding 10 ml of saline and I g of glass beads 3 mm in diameter.
The suspension was vortexed and, after decantation, the super-
natant was homogenized in an ultraturrax mixer for 15 to 20
seconds (20,000 rev . min). The number of spores was deter-
mined in a cell-counting chamber, and the number of CFU was
counted on agar plates by the serial dilution method. All
countings were done in quadruplicate.
Three experiments (A, B and C) were performed. In experi-
ments A and B (Tables 1 and 2), 27 ranked groups of six animals
were used for studying infection with Rh. rhizopodjformis and
Rh. oryzae. respectively. In experiment C (Table 3), eight
groups of eight animals were used for infection with Rh. oryzae.
All animals were kept in separate cages and received feed and
water ad libitum.
Experimental protocol. For the two fungal strains (experi-
ment A and B), a similar protocol was used for 13 and 14
experimental groups respectively (Tables I and 2). In these two
experiments, groups 3 to 11 were infected. Control groups 1, 2,
12, 13 and 14 were not infected and remained either untreated
(group 1), or were treated with amphotericin B (group 2), with
DFO (groups 12 and 13) or with DFO and amphotericin B
(group 14). In group 4, infection was accompanied by the
intraperitoneal (i.p.) injection of the excipient (1 ml of saline).
DFO, 50 mg (100 mg. kg, volume of 0.5 ml) was given
intramuscularly (i.m.) 24 hours before the infection in groups 4
to 16. In groups 6 and 7, it was given only once; in groups 8 and
9, it was given on two consecutive days (day —1 and just prior
to the infection); in groups 10 and 11, it was given on four
consecutive days (day —1 to day +2, with reference to the
infection). Amphotericin B was given in groups 2, 5, 7, 9, and 11
(i.p.) at a dose of 2.5 mg kg' for 14 days, as of the day of
infection. For the measurement of serum iron, 1 ml of blood
was taken from the orbital sinus before, and 6 and 24 hours after
administration of a single 50 mg dose of DFO in 108 animals
receiving DFO.
In experiment C (Table 3), groups I to 5 were infected with
Rh. oryzae, while groups 6 to 8 remained uninfected. Groups 2
and 6 received DFO for four days, as described above. In
groups 3 and 8, the animals were injected for four days (day —1
to +2) i.m. with feroxamine at 50 mg. Incubating stoichiometric
quantities of DFO and of Fe3 citrate hydrate in vitro during
two hours at 20°C generated feroxamine. In groups 4 and 7, the
animals were injected for four days (days —1 to +2) with only
Fe3 citrate hydrate, but in an equimolar dosage to DFO.
Group 5 separately received DFO and Fe3 citrate hydrate for
four days. DFO was injected i.m. into the left thigh muscle and
Fe3 citrate hydrate into the right thigh muscle.
Assessment. Animals were observed twice daily. Behavior
and survival were recorded. Animals surviving on day 28 after
infection were sacrificed. A necropsy was carried out on dead
and sacrificed animals. Cultures from seven organs per animal
(lung, liver, spleen, left kidney, brain, left eye and skin of the
back) were performed on Sabouraud agar at 37°C.
Van Cutsem and Boelaert: DFO and Fe in inucormycosis 1063
Table 2. Systemic zygomycosis induced by Rhizopus oryzae in guinea pigs (groups of 6): Treatment with deferoxamine and amphotericin B
Cultures
Group Infection
Treatment
DFO no.a Therapy
Survivors
no.
Mean survival
in days on
day 28
Statistics: pb
No. of pos. organs
(7 per animal°)
dead surviving
Statistics: pb
vs. group 5vs. group 3 vs. group 5
1 0 0 0 6 28 — 0/42
(saline)
2 0 0 Ad 6 28 — 0/42
3 + 0 0 0 8.8(0.41)e 40/42 —
4 + 0 saline 0 8.8 (0.41) 39/42 —
5 + 0 A 5 27.7 (0.82) 0.002 1/7 4/35
6 + 1 0 0 7.3 (1.86) 0.044 42/42 —
7 + I A 2 16.2 (11.0) 0.049 22/28 4/14 <0.001
8 + 2 0 0 6.2 (117) 0.004 42/42 —
9 + 2 A 1 10.7 (878) 0.013 34/35 1/7 <0.001
10 + 4 0 0 4.8 (0.41) 0.002 41/42 —
11 + 4 A 0 4.8 (1.60) 0.003 0.002 42/42 — <0.001
12 0 1 0 6 28 — 0/42
13 0 4 0 6 28 — 0/42
14 0 4 A 6 28 — 0/42
a Deferoxamine, 50 mg i.m. per injectionb Mann-Whitney U test (two-tailed probability) for comparing survival; Chi-square test (two-tailed probability) for comparing culture resultsC 7 organs: lungs, liver, spleen, left kidney, brain, skin and left eye (6 animals per group)d Amphotericin B, 2.5mg kg' i.p. during 14 days, starting on the day of infection
(0.41): standard deviation
Table 3. Systemic zygomycosis induced by Rhizopus oryzae in guinea pigs (groups of 8): Treatment with deferoxamine, feroxamine and iron
citrate hydrate
Cultures
Group Infection Treatment
Survivors
no.
Mean survival
in days on
day 28
Statistics: P
No. of pos. organsb
(7 per animal)
vs. group I vs. group 2 vs. group 4 dead surviving
1 + 0 0 7.8(l.91)C 56/56 —
2 + 4 x DFO" 0 3.5 (0.53) <0.001 <0.007 56/56 —
3 + 4 x Foe 0 3.0 (0) <0.001 0.025 <0.001 56/56 —
4 + 4 x Fe3 citr. hydrY 0 4.6 (0.74) 0.0011 0.007 56/56 —
S + 4 x
4 x
DFO,
Fe3 citr. hydr.
0 3,0 (0) <0.001 0.025 <0.001 56/56 —
6 0 4x DFO 8 28 — 0/56
7 0 4 x Fe3 citr. hydr. 8 28 — 0/56
8 0 4x FO 8 28 — 0/56
a Mann-Whitney U test (two-tailed probability)b 7 organs: lungs, liver, spleen, left kidney, brain, skin and left eye
(1.91): standard deviationd Deferoxamine
e Feroxamine, obtained by 2 hours in vitro incubation at 20°C of stoichiometric quantities of DFO and FE3 citrate hydrate
Fe citrate hydrate
Serum analysis. Total serum iron was determined without
deproteinization (with Ferrozine, registered trademark of Hach
Chemical Co., Ames, Iowa, USA). Fe3 was separated from
transferrin by means of a detergent combination in the weakly
acidic pH range and reduced to Fe2 with ascorbic acid. Fe2
then formed a colored complex with Ferrozine [91. Serum iron
was determined by the Boehringer Mannheim automated analy-
sis for BM/Hitachi System 717.
The serum concentration of total DFO, corresponding to the
sum of free DFO plus both its aluminum and its iron chelate,
was measured by Zeeman atomic absorption spectrometry [10].
These determinations were performed by Prof. M.E. De Broe
(Department of Nephrology, University of Antwerp, Antwerp,
Belgium).
Statistical analysis
Mean values are given together with standard deviation.
Comparisons between groups were made by the two-tailed
probability Mann-Whitney U test and the chi-square test for
survival and cultures, respectively.
Results
In vitro
Fungal development was faster at 37°C than at 25°C, but the
results at the two temperatures were comparable. The in vitro
results at 37°C are shown in Figures 1 and 2. The development
of both Rh. rhizopodformis and Rh. oryzae was favored by the
presence of either DFO or Fe3 at all concentrations tested
Rhizopus oryzae
A,C: DFO
mmol
O—O 0
• •i
O---O 0.1L— 0,01
A----A 0.001
B, D: Fe3
mmol
O—O 0
• •i
O----O 0.1
—A 0.01
A----A 0.001
(Fig. 1). The combination of DFO and Fe3 similarly promoted
the growth of both fungi (results not shown).
The antifungal activity of amphotencin B at 0, 1 and 100g. ml, either alone or in association with DFO, combined
with Fe3 at several concentrations is shown in Figure 2
(results only shown for Rh. rhizopodiformis). The results ob-
tained for the two strains were comparable. Amphotericin B
was active in vitro against both fungi. In tubes containing
amphotericin B, DFO and Fe3, the antifungal potency was
reduced. The degree of reduction of antifungal activity was
directly related to the concentration of DFO and of Fe3 .
Indeed, when DFO and Fe3 were present at 0.1 mmol or more,
fungal growth was increased for each of the amphotericin B
concentrations tested. The pH of uninoculated Sabouraud broth
was 6.39. After incubation with each fungal strain at 25°C the
pH dropped to a minimum of 4.0; with incubation at 37°C the
pH rose after day 9 from 4.7 to alkalinity.
in vivo
Tables 1 and 2 show the results for animal survival and for
organ cultures after infection with Rh. rhizopodiformis and Rh.
oryzae, respectively. The results obtained with the two strains
are comparable. Intravenous infection without drug treatment
(group 3) caused death in all animals on day 4.2 0.4 for Rh.
rhizopodiformis and on day 8.8 0.4 for Rh. oryzae. For both
strains, amphotericin B (group 5) was very efficacious, since
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Fig. 1. Effect of various concentrations of DFO
(A, C) and of Fe (B, D) on the growth of Rh.
rhizopodiformis (A, B) and Rh. oryzae (C, D) in
vitro at 37°C. One hundred percent represents
complete covering of the culture medium by
aerial mycelium; 110% represents abundant
sporulation. Symbols are:
234567 234567
Time, days Time, days
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only one out of six animals died, and survival at 28 days was
significantly increased, from 4.2 0.4 to 25.5 6.2 days after
Rh. rhizopodiformis infection and from 8.8 0.4 to 27.7 0.8
days after Rh. oryzae infection. Infected guinea pigs receiving
DFO (group 6, 8 and 10) looked ill earlier than those not
receiving the drug. DFO significantly enhanced the infection,
and mean survival was significantly shorter in the treated than
in the untreated groups (group 3); the latter effect was dose-
dependent. Moreover, DFO significantly decreased the thera-
peutic effect of amphotericin B (groups 7, 9, 11), the decrease in
survival being dose-dependent. In the untreated group (group
3), examination of the buffy coat after Grocott staining on day
5 after infection with Rh. oryzae did not show any circulating
fungal element. However, the infection was disseminated, as
the fungus could be recovered from 40 out of the 42 organs
cultured after infection with spores from each of the two fungal
strains. This contrasts with the amphotericin B-treated animals
(group 5), in which only seven and five organs, respectively, out
of 42 had positive fungal cultures. DFO significantly increased
the rate of positive cultures in the amphotericin B-treated
groups.
In the absence of infection, DFO treatment (groups 12 and
13), amphotericin B treatment (group 2) and combined treat-
ment with DFO and with amphotericin B (group 14) resulted in
the survival of all animals and the absence of positive fungal
cultures in all cases.
The non-infected guinea pigs (N = 108) had a normal iron
status, as indicated by a baseline mean serum iron value of
255.4 48.4 gIdl. In the animals in group 6, total DFO was
assayed in serum six hours after a single DFO administration.
At this time, DFO and its chelates were no longer detectable.
As the results obtained after infection with Rh. rhizopodi-
formis and Rh. oryzae were very similar (Tables I and 2),
experiment C was limited to experimental mucormycosis
caused by Rh. oryzae. Table 3 compares the effect of DFO,
feroxamine and Fe3 citrate on the course of infection. The
Fig. 2. Growth of Rh. rhizopodiformis on day 4
(A) and on day 7 (B). Effect of various
concentrations of DFO ÷ Fe3 (in stoichiometric
quantity) on the antifungal effect of amphotericin
B at concentrations of 1 and 100 g ml. One
hundred percent represents complete covering of
the culture medium by aerial mycelium; 110%
represents abundant sporulation. Symbols are:
DFO + Fe3
mmol mmol
• •l +1
O—O0.l + 0.1
•----• 0.01 + 0.01
O----O0 +0
significant shortening of survival (from 7.8 1.9 to 3.5 0.5
days) in group 2 with four doses of DFO was comparable to that
obtained in experiment B (Table 2), where survival decreased
from 8.8 0.4 to 4.8 0.4 days. Similarly, feroxamine (group
3), as well as the combined treatment of DFO and Fe3 citrate
(group 5), significantly shortened survival (each to 3 days).
Survival was significantly shorter after treatment with feroxam-
me or the combination of DFO and Fe3 citrate than after DFO.
Fe3 citrate alone (group 4) also significantly decreased sur-
vival to 4.6 0.7 days. However, the effect of Fe3 citrate
alone upon survival of infected animals was significantly
smaller than that of DFO, feroxamine or DFO + Fe3 citrate.
In the absence of infection (groups 6 to 8), none of these
treatments affected survival.
Discussion
Recent reports on mucormycosis in 25 dialysis patients, 22 of
whom were treated with DFO when the infection developed,
point to a probable cause-and-effect relationship between this
drug therapy and the Rhizopus infection [1—71. On the other
hand, DFO treatment in dialysis patients does not increase the
incidence of bacteremias [11, 12]. This suggests that DFO
therapy in such patients selectively increases the risk of mu-
cormycosis. It was these clinical data that prompted the present
investigation on the effect of DFO on experimental mucormy-
cosis.
Two different fungal strains were used: one isolated from a
dialysis patient who died from mucormycosis while on DFO
therapy (Rh. rhizopodiformis), the other isolated from a non-
uremic patient with leukemia who died of mucormycosis while
not treated with DFO (Rh. oryzae). The in vitro and in vivo
studies were performed with both strains. One of us (JVC) has
shown before that the intravenous injection of spores from
either fungal strain in the guinea pig leads to a disseminated
mucormycosis which rapidly becomes fatal [13]. This course
was similar to that observed in dialysis patients. Survival time
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after infection in the guinea pig was highly reproducible, being
shorter after infection with Rh. rhizopodiformis than with Rh.
oryzae [13]. It is assumed that in the clinical setting, the likely
portal of entry of disseminated mucormycosis is the respiratory
tract [8, 14]. However, experimental mucormycosis by inhala-
tion or by intranasal instillation is not possible, except in the
diabetic animal, in which, however, survival time is more
unpredictable [13]. For these reasons, the intravenous route of
infection was chosen. The fact that iron metabolism in the
guinea pig is similar to that in man was another reason for
choosing the guinea pig [15]. The iron status of the healthy
guinea pigs studied was normal, as indicated by their mean
serum iron concentration of 255.4 48.4 p.g per dl [16].
Intravenous infection with 293 CFU of Rh. rhizopodformis
per gram body weight and with 3,550 CFU of Rh. oryzae per
gram body weight led to mean survival times that were similar
to the previous report, confirming the highly reproducible
course of this experimental infection [13], The lower inoculum
size needed to cause fatal infection in the guinea pig with Rh.
rhizopodformis than with Rh. oryzae could be due to a greater
pathogenicity of the former.
Guinea pigs infected with either of the Rhizopus strains
studied were somnolent after 48 hours, becoming rapidly apa-
thetic and lethargic when pretreated with DFO. Treatment of
the infected animals with 50 mg of DFO significantly shortened
survival in function of the number of DFO administrations. This
effect of DFO cannot be ascribed to toxicity of the drug itself,
since survival of the noninfected animals receiving DFO was
unaffected. The dosage of 50 mg of DFO was chosen because it
was known to enhance infections with Yersinia enterocolitica in
the guinea pig [171.
The evidence on the effect of DFO on experimental infections
with microorganisms other than th genus Rhizopus is con-
flicting, given that DFO has been shown to enhance some
infections (such as Yersinia enterocolitica) and to protect
against others (such as Listeria monocytogenes). This disparate
effect of DFO upon experimental infections has been related by
Robins-Browne and Prpic to the ability or inability of the
infecting microorganism to use the iron-chelate of DFO, ferox-
amine [17]. It is thus believed that microorganisms that have a
receptor for feroxamine would be stimulated in their growth by
the iron that can be provided by feroxamine. Experiment C
(Table 3) indicates that not only DFO, but also feroxamine,
obtained by incubating stoichiometric quantities of DFO and of
Fe3 in vitro, significantly shortens survival of guinea pigs
infected with Rh. oryzae. When DFO and Fe3 were given
separately, leading to the in vivo formation of feroxamine, the
effect was the same. These data make it highly likely that the
enhancement of Rhizopus infection in the guinea pig by DFO is
mediated by the in vivo formation of feroxamine, for which
fungi of the Rhizopus genus probably have a receptor. How-
ever, a direct proof of the existence of such a receptor in these
fungi is presently lacking. Several fungi have been reported to
be capable of siderophore production during iron limitation [18,
19]. These futigal siderophores belong to the hydroxamate class
and in the case of some fungi, have been characterized by
high-performance liquid chromatography [181. It should be
stressed that DFO is also a trihydroxamate. More specifically,
Holzberg and Artis reported that Rh. oryzae, when grown in an
iron-poor medium, is capable of producing a siderophore of the
hydroxamate type [191. This contrasts with pathogenic Yersinia
enterocolitica strains, which are also believed to have a recep-
tor for feroxamine but seem incapable of producing a sidero-
phore [17]. It should be noted that experimental infections
caused by Yersinia enterocolitica are enhanced by DFO [17].
However, when observed in dialysis patients, bacteremias
caused by Yersinia enterocolitica seem more related to iron
overload than to DFO therapy [20].
Injection of Fe3 citrate also significantly shortened survival
of the animals infected with Rh. oryzae, although the effect of
Fe3 + citrate alone upon survival was significantly smaller than
that obtained by either DFO, feroxamine or the combination of
DFO with Fe3 citrate. A link between iron and an increased
susceptibility to mucormycosis has been suggested in several
studies. First, Corbel and Eades reported in their studies on
experimental phycomycosis in mice, that suspending spores of
Absidia ramosa in a solution containing Fe2 ions markedly
increases the numbers of animals developing lethal infection
[21]. Second, Abe et al found that mice, in which diabetic
ketoacidosis was experimentally induced, died after i.v. infec-
tion with Rh. oryzae spores, while infected control mice sur-
vived [221. These authors suggested that the low unbound
iron-binding capacity due to acidosis plays an important role in
promoting this infection [22]. Third, Artis et at found that
increasing the iron content of iron-poor diabetic ketoacidotic
human serum that does not support the growth of Rh. oryzae
permits profuse growth under acidotic conditions [23]. Fourth,
two of the three dialysis patients in whom mucormycosis
occurred in the absence of DFO therapy had transfusional iron
overload [6, 241.
The in vitro results obtained in the present study complement
the in vivo results. Indeed, for both Rhizopus strains studied,
DFO, as well as Fe3 citrate, had a significant stimulatory effect
on fungal growth and sporutation, as tested in Sabouraud broth
with a low iron content (0.45 ppm). This stimulatory effect was
not only very pronounced at the 1 mmol concentrations, but it
was also observed at the 0.001 mmol concentrations.
Are the DFO concentrations that were used in the present in
vitro study to demonstrate a stimulatory effect on the growth of
Rhizopus relevant to the DFO concentrations attained in vivo in
dialysis patients? The fact that DFO and its chelates could no
longer be detected in the plasma six hours after the administra-
tion of 50 mg of DFO to the guinea pigs is consistent with the
rapid removal of these substances by mainly renal but also
biliary excretion [25]. However, in patients on maintenance
dialysis, the half-life of DFO and of feroxamine is prolonged
during the interdialytic period [25]. De Broe et al reported that
the plasma half-life of total DFO (that is, the sum of unchelated
DFO, feroxamine and aluminoxamine) increased from 85 min-
utes in patients with normal renal function to 555 minutes in
dialysis patients, and to 1507 minutes in dialysis patients with
concomitant hemosiderosis and liver dysfunction [261. The
corresponding maximal feroxamine plasma levels increased
from 9.6 molIliter in the normal renal function group to 31.4
smolIliter in the dialysis patients with liver dysfunction [26]. De
Broe et a! showed that the plasma feroxamine concentration in
dialysis patients remains at a high level during the whole
interdialytic period [26]. Because of these pharmacokinetic
data, the present study in non-uremic animals does not permit
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an extrapolation of the risk of mucormycosis according to
different DFO dosages in dialysis patients.
Amphotericin B, as opposed to antifungals from the azole
group, is active against Rhizopus [27]. The dose-dependent
decrease in in vitro growth and sporulation of Rhizopus by
amphotericin B is confirmed in the present study. Moreover,
amphotericin B significantly reduced the mortality of the guinea
pigs infected with either of the Rhizopus strains studied. This
antifungal drug also led to a significant reduction in positive
fungal cultures. Although the amphotericin B dosage used in the
guinea pig (2.5 mg kg per day) exceeds the clinical thera-
peutic dosage in man (0.5 to 1 mg kg per day), the former is
the active and non-toxic dosage in guinea pigs [27]. This
corresponds to higher doses on a mg per kg base needed in
small animals compared to man. Interestingly, the beneficial
effect of amphotericin B in vivo was significantly inhibited by
the concomitant use of DFO, this inhibition being a function of
the number of DFO doses administered. Similarly, the growth
reduction caused in vitro by amphotericin B was reversed by
the presence in the broth medium of both DFO and Fe3 in
stoichiometric concentrations. Increasing the concentration of
both DFO and Fe3 led to an increased reversal of the growth
inhibition owing to amphotericin B. The mechanism of this
effect is unclear but it could be viewed as a balance between a
growth-inhibiting factor (amphotericin B) and growth-en-
hancing factors (DFO + Fe3). The influence of DFO (with or
without Fe3) on the antifungal effect of amphotericin B upon
other fungi has to be studied to eliminate the possibility of a
drug to drug interaction. The practical implication of these
observations is that treatment of mucormycosis by amphoteri-
cm B has little chance of being successful if DFO therapy is
maintained. As soon as the diagnosis of mucormycosis is
suspected, DFO therapy should be immediately stopped.
Several questions on the pathogenesis of mucormycosis in
dialysis patients remain unanswered, such as the respective
roles of uremia, acidosis and aluminum overload. These ques-
tions were not examined in the present study on healthy guinea
pigs. As the animals were not uremic, aluminum overload could
not be induced experimentally. However, a primary role for
these factors, alone or combined, is unlikely for the following
reasons. First, mucormycosis has only rarely been reported in
nondialyzed patients with stable chronic renal failure, and only
3 of the 25 dialysis patients reported to have mucormycosis
were not receiving DFO. This observation contrasts with re-
ports on mucormycosis in 22 dialysis patients treated with
DFO, given that only a minority of dialysis patients receive this
drug [1]. Second, mucormycosis—whenever identified—caused
by either Rhizopus or Cunninghamella bertholletiae, has also
been reported in seven patients with iron-overload treated with
DFO [28—34]; none of these patients had uremia (potentially
complicated by acidosis or aluminum overload). It is therefore
unlikely that uremia, acidosis and aluminum overload play a
primary role in the pathogenesis of mucormycosis in dialysis
patients. These factors could nevertheless play an adjunctive
role: that is, uremia, by increasing the plasma feroxamine
concentration for prolonged periods, and acidosis, by decreas-
ing the binding of iron to transferrin, thus making more iron
available. Although the present study shows that enhancement
of experimental mucormycosis in vivo by DFO, as well as by
feroxamine, could be explained by a drug-induced stimulation
of the growth of Rhizopus in vitro, other effects of DFO cannot
be excluded. Indeed, DFO has been reported to have various
effects on phagocytes and lymphocytes [35—40]. The possible
interplay between DFO and cells involved in the defense
against Rhizopus, particularly in dialysis patients, needs further
investigation.
In conclusion, this investigation shows that the healthy
guinea pig can provide a reproducible model for studying
disseminated mucormycosis caused by two different Rhizopus
strains. In this model, DFO, its iron chelate feroxamine and
Fe3 all enhanced the infection, causing decreased animal
survival. DFO also decreased the therapeutic efficacy of am-
photericin B. DFO and Fe3, both alone and in combination,
stimulated the growth of both Rhizopus strains in vitro and
reversed the growth inhibition due to amphotericin B. The
nephrologist treating dialysis patients with DFO should be
highly vigilant regarding the possible development of mucormy-
cosis. Studies are needed on the efficacy of DFO at a lower
dosage and the incidence of mucormycosis at this dosage. The
search for other chelators without siderophore activity should
also continue.
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Note added in proof
An international registry of cases of mucormycosis (zygomycosis)
developing during long-term dialysis has been established (BOELAERT
JR et al: Mucormycosis among patients on dialysis. N Engi J Med
321:190—191, 1989). Cases may be reported to J.R. Boelaert.
Reprint requests to J. Van Cutsem, Department of Bacteriology and
Mycology, Janssen Research Foundation, B-2340 Beerse, Belgium.
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